Tau Degrader Compound Screening Data from Patient iPSC-Derived Neurons

A 2026 medicinal chemistry campaign employed frontotemporal dementia patient induced pluripotent stem cell (iPSC)-derived neurons to screen tau-targeting protein degraders. The dataset details structure-activity relationships and identifies lead compounds, including QC-01-175, based on their tau degradation efficiency in human ex vivo neuronal models. The work was authored by M. Catarina Silva and published on figshare.

Use Cases

• Establish structure-activity relationships (SAR) for tau degrader chemical series using degradation efficiency metrics from mutant neuronal assays.
• Identify lead compounds like QC-01-175 by analyzing tau degradation activity data in FTD-patient iPSC-derived neurons.
• Optimize molecular composition for tau degradation by comparing activity data across different chemical series tested in the primary neuronal models.

Strengths

• Data is derived from human FTD-patient iPSC-derived neurons, providing a disease-relevant genomic and physiological context.
• The dataset supports the identification of three final lead molecules with demonstrated tau degradation activity.

Limitations

• The dataset is small in scale at 339.7 KB, indicating limited raw data volume.
• Specific sample sizes, row counts, and detailed experimental measurements are not provided.
• The data is specific to a single tau variant or mutation model, limiting generalizability to other tauopathies.

Provenance

Source

M. Catarina Silva, published on figshare.

Collection Method

Screening of tau-targeting degrader compounds in FTD-patient iPSC-derived neuronal models.

Time Range

Campaign and data generation circa 2026.

Freshness

null

Geography

null